Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Heart & blood · 2025

Myqorzo (aficamten)

The FDA approved Myqorzo (aficamten) on December 19, 2025 to treat symptomatic obstructive hypertrophic cardiomyopathy.
Brand name
Myqorzo
Generic name
aficamten
FDA approval date
December 19, 2025
Approved use (FDA wording)
To treat symptomatic obstructive hypertrophic cardiomyopathy
Company
Cytokinetics
Application
NDA219083
Dosage form / route
TABLET · ORAL
Boxed warning on label
Yes (see the FDA label)
Category on this site
Heart & blood

Indications and usage, from the FDA label

MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. ( 1 )

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.